MicroRNAs and lncRNAs—A New Layer of Myeloid-Derived Suppressor Cells Regulation

Safarzadeh, Elham; Asadzadeh, Zahra; Safaei, Sahar; Hatefi, Arash; Derakhshani, Afshin; Giovannelli, Francesco; Brunetti, Oronzo; Silvestris, Nicola; Baradaran, Behzad

doi:10.3389/fimmu.2020.572323

Cited by 20 publications

(20 citation statements)

References 156 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The development of MDSCs is a complex phenomenon consisting of increased production of IMCs in the bone marrow, inhibition of the terminal differentiation of IMCs, and pathological activation of MDSCs. Multiple factors secreted from cancer or stromal cells, such as macrophage colony-stimulating factor, granulocyte colony-stimulating factor (G-CSF), granulocyte monocyte colony-stimulating factor, vascular endothelial growth factor (VEGF), transforming growth factor-beta (TGF-β), tumor necrosis factor-alpha, prostaglandin E2 (PGE2), interleukins (IL-1β, IL-10, IL-4, and IL-6), and noncoding RNAs (microRNAs and long noncoding RNAs) are involved in these processes [ 4 , 8 , 10 ]. In addition to these, recent investigations have suggested that tumor-derived exosomes are involved in the development of MDSCs through the communication with bone marrow cells [ 11 ].…”

Section: Mdsc Development Activation and Recruitmentmentioning

confidence: 99%

Myeloid-Derived Suppressor Cells as Therapeutic Targets in Uterine Cervical and Endometrial Cancers

Mabuchi

Sasano

2021

Cells

View full text Add to dashboard Cite

Uterine cervical and endometrial cancers are the two most common gynecological malignancies. As demonstrated in other types of solid malignancies, an increased number of circulating or tumor-infiltrating myeloid-derived suppressor cells (MDSCs) have also been observed in uterine cervical and endometrial cancers, and increased MDSCs are associated with an advanced stage, a short survival, or a poor response to chemotherapy or radiotherapy. In murine models of uterine cervical and endometrial cancers, MDSCs have been shown to play important roles in the progression of cancer. In this review, we have introduced the definition of MDSCs and their functions, discussed the roles of MDSCs in uterine cervical and endometrial cancer progression, and reviewed treatment strategies targeting MDSCs, which may exhibit growth-inhibitory effects and enhance the efficacy of existing anticancer treatments.

show abstract

Section: Mdsc Development Activation and Recruitmentmentioning

confidence: 99%

Myeloid-Derived Suppressor Cells as Therapeutic Targets in Uterine Cervical and Endometrial Cancers

Mabuchi

Sasano

2021

Cells

View full text Add to dashboard Cite

show abstract

“…However, the complex microenvironment of tumors can mediate immune escape, leading to the failure of immunotherapy [56]. lncRNAs are overexpressed during the development, differentiation and activation of immune cells, such as macrophages, dendritic cells, neutrophils, T cells, B cells and bone marrow mesenchymal stem cells [57]. Recent studies have found that lncRNAs are involved in various processes of the immune response in the TME and the promotion of tumor immunosuppression [58] and play a role in the evaluation and measurement of the immunotherapeutic response in various cancers, such as endometrial cancer and liver cancer [59][60].…”

Section: Discussionmentioning

confidence: 99%

N6-methyladenosine-related lncRNAs as a biomarker for predicting the prognosis and immune microenvironment of clear cell renal cell carcinoma

Qiu

Wang

Fan

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Patients with advanced clear cell renal cell carcinoma (ccRCC) have a poor prognosis and lack effective prognostic biomarkers. This study uses bioinformatics analysis to identify N6-methyladenosine-related lncRNAs (m6A-related lncRNAs) as new prognostic biomarkers for ccRCC.Methods: Gene expression data and related clinical information of ccRCC patients were extracted from the Cancer Genome Atlas Database. m6A-related lncRNAs were obtained by co-expression analysis. Univariate Cox regression analysis was performed on these lncRNAs to find the prognostic-related m6A-related lncRNAs, and consensus clustering analysis was performed. The prognostic signature was screened by LASSO regression and a prognostic model was constructed. The predictive performance of the prognostic model was evaluated and validated by survival analysis and ROC curve analysis, etc. In addition, we also systematically analyzed the expression of immune checkpoints and immune cell infiltration in ccRCC patients.Results: First, 27 m6A-related lncRNAs associated with prognosis were identified, which were significantly differentially expressed between tumor and normal tissues. Consensus clustering analysis indicated that cluster 2 was associated with poor prognosis, low stromal score, high expression of PD-1, PD-L1, CTLA-4, LAG-3, TIM-3, TIGIT, and immunosuppressive cell infiltration. The signaling pathways related to tumor progression, drug resistance, and angiogenesis and biological processes related to protein methylation and phosphatidic acid metabolism are significantly enriched in cluster 2. Subsequently, LASSO regression analysis was used to construct a prognostic risk model based on 7 m6A-related lncRNAs signature, which can be used as an independent prognostic indicator. After a series of analyses, it was shown that this model had good sensitivity and specificity, can predict the prognosis of patients with different clinical stratifications and was associated with the progression of ccRCC. The expression levels of immune checkpoints were significantly increased in high-risk patients, and there was a certain correlation between the risk score and immune cell infiltration. Conclusions: In summary, we constructed and validated a risk model that can independently predict the prognosis of ccRCC patients and reflect the immune microenvironment based on m6A-related lncRNAs; the model is conducive to the screening of biomarkers of ccRCC prognosis and may have the potential to reflect the response of ccRCCs to immunotherapy.

show abstract

“…Nonetheless, the number of miRs contributing to MDSCs function is increasing and has been reviewed in detail elsewhere. 107…”

Section: Myeloid-derived Suppressor Cellsmentioning

confidence: 99%

Transforming growth factor‐beta1 and myeloid‐derived suppressor cells: A cancerous partnership

Mojsilović

Bjelica

et al. 2021

Developmental Dynamics

View full text Add to dashboard Cite

Transforming growth factor-beta1 (TGF-β1) plays a crucial role in tumor progression. It can inhibit early cancer stages but promotes tumor growth and development at the late stages of tumorigenesis. TGF-β1 has a potent immunosuppressive function within the tumor microenvironment that largely contributes to tumor cells' immune escape and reduction in cancer immunotherapy responses. Likewise, myeloid-derived suppressor cells (MDSCs) have been postulated as leading tumor promoters and a hallmark of cancer immune evasion mechanisms. This review attempts to analyze the prominent roles of both TGF-β1 and MDSCs and their interplay in cancer immunity. Furthermore, therapies against either TGF-β1 or MDSCs, and their potential synergistic combination with immunotherapies are discussed. Simultaneous TGF-β1 and MDSCs inhibition suggest a potential improvement in immunotherapy or subverted tumor immune resistance.

show abstract

MicroRNAs and lncRNAs—A New Layer of Myeloid-Derived Suppressor Cells Regulation

Cited by 20 publications

References 156 publications

Myeloid-Derived Suppressor Cells as Therapeutic Targets in Uterine Cervical and Endometrial Cancers

Myeloid-Derived Suppressor Cells as Therapeutic Targets in Uterine Cervical and Endometrial Cancers

N6-methyladenosine-related lncRNAs as a biomarker for predicting the prognosis and immune microenvironment of clear cell renal cell carcinoma

Transforming growth factor‐beta1 and myeloid‐derived suppressor cells: A cancerous partnership

Contact Info

Product

Resources

About